Cognitive Impairment Related to Atrial Fibrillation Prevention Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT01994265

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01994265
Other papers using this trial's data
  • Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial BMC medicine, 2022-10-26 DOI, PubMed 36284318, PMC9598018 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01994265. Randomized; single masking; primary purpose prevention. Start 2014-11-07 (registry gives no type); primary completion 2021-03-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cognitive Impairment Related to Atrial Fibrillation Prevention Trial
Acronym
GIRAF
Intervention (Drug)
Warfarin
Intervention (Drug)
Dabigatran
Lead sponsor
University of Sao Paulo (class: other)
Collaborator
Federal University of Minas Gerais (class: other)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct01994265
Content hash
8e3fa6c545f29834200e0d07caba238224b45fc4b8b0d67cf1e2c9bf85e33102